Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
Contact: Study coordinator (Minghui Wang, Dr.) · wmingh@mail.sysu.edu.cn · 13826276828
Contact: Principal Investigator (Minghui Wang, Dr.)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States

Advanced Unresectable Gastric Adenocarcinoma · Esophageal Squamous Cell Carcinoma · Advanced Gastroesophageal Adenocarcinoma

Abroad (travel likely)RecruitingPHASE2

Los Angeles, United States · Hialeah, United States

Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Pittsburgh, United States · Natal, Brazil

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

Advanced Solid Tumors · Genital Neoplasm, Female · Urogenital Neoplasms

Abroad (travel likely)RecruitingPHASE1, PHASE2

Loma Linda, United States · Sacramento, United States

A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)

Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2, PHASE3

Beijing, China